 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Medical News United States: Pfizer to Expand Access to HIV DrugDecember 5, 2006 On Friday, Pfizer Inc. announced plans to allow HIV/AIDS patients expanded access to a drug not yet approved by regulators but in late-stage clinical trials. Maraviroc belongs to the CCR5 antagonists class of drugs; these work by trying to block HIV from gaining entrance to white blood cells, rather than by fighting the virus inside the cells. The new program will allow patients resistant to other treatments to begin accessing the new drug. In the next few months, Pfizer will start enrolling patients from more than 30 countries in the program, in which they will receive the new drug along with background therapy. Researchers will monitor their progress. Associated Press 12.01.2006  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
